Payment overview · 2025
General Payments
$226.61
11 reported records · 7 companies
Healthcare provider profile · identity verified
Robert Morris Harpold, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PORT ORANGE, FL · NPI 1134172497
Verified facts
What the public records show
CMS Open Payments records show Robert Morris Harpold, M.D. received $226.61 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.62 | 21.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.63 | 19.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.53 | 19.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.83 | 14.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.01 | 12.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.46 | 7.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.53 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $226.61 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.62 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.62 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.63 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.53 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.53 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.01 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 133 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 565 | 188 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 100 |
| Losartan Potassium | Losartan Potassium | 303 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 89 |
| Lisinopril | Lisinopril | 252 | 88 |
| Omeprazole | Omeprazole | 250 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 77 |
| Prednisone | Prednisone | 206 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 67 |
| Gabapentin | Gabapentin | 176 | 66 |
| Metformin Hcl | Metformin Hcl | 160 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 23 |
| Alprazolam | Alprazolam | 143 | 28 |
| Furosemide | Furosemide | 139 | 55 |
| Eliquis | Apixaban | 133 | 41 |
| Trazodone Hcl | Trazodone Hcl | 133 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 31 |
| Montelukast Sodium | Montelukast Sodium | 113 | 39 |
| Carvedilol | Carvedilol | 112 | 36 |
| Ozempic | Semaglutide | 108 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 105 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 38 |
| Valsartan | Valsartan | 103 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 35 |
| Ezetimibe | Ezetimibe | 100 | 38 |
| Simvastatin | Simvastatin | 98 | 35 |
| Tramadol Hcl | Tramadol Hcl | 94 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 35 |
| Alendronate Sodium | Alendronate Sodium | 91 | 27 |
| Pregabalin | Pregabalin | 91 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 31 |
| Allopurinol | Allopurinol | 82 | 24 |
| Celecoxib | Celecoxib | 82 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 26 |
| Lorazepam | Lorazepam | 78 | 15 |
| Sertraline Hcl | Sertraline Hcl | 77 | 30 |
| Finasteride | Finasteride | 74 | 25 |
| Temazepam | Temazepam | 74 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 71 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 25 |
| Meloxicam | Meloxicam | 65 | 24 |
| Farxiga | Dapagliflozin Propanediol | 64 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 30 |
| Buspirone Hcl | Buspirone Hcl | 60 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 18 |
| Jardiance | Empagliflozin | 58 | 18 |
| Bupropion Xl | Bupropion Hcl | 55 | 20 |
| Lovastatin | Lovastatin | 54 | 20 |
| Calcitriol | Calcitriol | 53 | 16 |
| Famotidine | Famotidine | 53 | 21 |
| Potassium Chloride | Potassium Chloride | 53 | 21 |
| Glimepiride | Glimepiride | 52 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 44 |
| Diazepam | Diazepam | 51 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 16 |
| Nifedipine Er | Nifedipine | 50 | 17 |
| Cefuroxime | Cefuroxime Axetil | 49 | 48 |
| Glipizide | Glipizide | 48 | 15 |
| Ondansetron Odt | Ondansetron | 46 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 44 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 13 |
| Lamotrigine | Lamotrigine | 43 | 11 |
| Atenolol | Atenolol | 42 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 13 |
| Donepezil Hcl | Donepezil Hcl | 41 | 15 |
| Mirtazapine | Mirtazapine | 41 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 15 |
| Amoxicillin | Amoxicillin | 38 | 34 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 12 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 11 |
| Valacyclovir | Valacyclovir Hcl | 32 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 28 |
| Irbesartan | Irbesartan | 29 | 12 |
| Synthroid | Levothyroxine Sodium | 29 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 16 |
| Tadalafil | Tadalafil | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | 14 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Mupirocin | Mupirocin | 24 | 19 |
| Primidone | Primidone | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 17 |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Cephalexin | Cephalexin | 17 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Topiramate | Topiramate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 11 |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Rezvoglar Kwikpen | Insulin Glargine-Aglr | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $226.61 · 11 records | PFIZER INC. | Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Kerendia, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error